Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6886 to 6900 of 7704 results

  1. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued [GID-TA10243]

    Technology appraisal guidance
    Discontinued

  2. Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]

    In development [GID-TA10851] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]

    In development [GID-TA10906] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development [GID-TA10899] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development [GID-TA10900] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

    In development [GID-TA10728] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Diabetes - buccal insulin [ID311]

    Discontinued [GID-TAG244]

    Technology appraisal guidance
    Discontinued

  8. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued [GID-TAG496]

    Technology appraisal guidance
    Discontinued

  9. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued [GID-TAG494]

    Technology appraisal guidance
    Discontinued

  10. ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

    Discontinued [GID-TA10445]

    Technology appraisal guidance
    Discontinued

  11. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued [GID-TA10345]

    Technology appraisal guidance
    Discontinued

  12. Intravenous zanamivir for treating influenza in hospital [ID1196]

    Discontinued [GID-TA10298]

    Technology appraisal guidance
    Discontinued

  13. Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

    Discontinued [GID-TA10332]

    Technology appraisal guidance
    Discontinued

  14. Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

    Discontinued [GID-TA10522]

    Technology appraisal guidance
    Discontinued

  15. Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]

    In development [GID-TA10589] Expected publication date: TBC

    Technology appraisal guidance
    In development